5 Cash-Rich Dividend Stocks to Invest In Right Now

2. Bristol-Myers Squibb Company (NYSE:BMY)

Operating Cash Flow (TTM): $14.16 Billion

On April 9, BofA analyst Jason Gerberry lowered the price recommendation on Bristol-Myers Squibb Company (NYSE:BMY) to $67 from $68. It reiterated a Buy rating on the shares. The firm made several adjustments alongside its Q1 preview for large-cap pharma and small- to mid-cap biopharma coverage.

During the Q4 2025 earnings call, management said it expects 2026 revenue to come in between $46 billion and $47.5 billion. The company pointed to steady performance in its growth portfolio, while also noting that a 12% to 16% decline in the legacy portfolio is likely as exclusivity losses continue to weigh on results. The company also expects Eliquis to grow by 10% to 15% in 2026. Adjusted diluted EPS is projected in the range of $6.05 to $6.35.

CFO David Elkins said gross margins are expected to be between 69% and 70%. He also noted that total operating expenses should decline from 2025 levels to around $16.3 billion. Looking ahead, management indicated that Eliquis sales could fall by $1.5 billion to $2 billion in 2027 compared to 2026, mainly due to patent expirations in Europe.

Bristol-Myers Squibb Company (NYSE:BMY) operates as a global biopharmaceutical company focused on developing and delivering medicines for serious diseases. Its work spans oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.